Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Respiratory
- Viral Infection
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 304649
License Grant
This license grants the Canadian Licensee worldwide rights, other than in Greater China, Japan and ASEAN countries, to commercialize and sell AntiCovir.
License Property
Licensor developed the formulation and potential uses of AntiCovir as a treatment or a prophylaxis for COVID-19.
AntiCovir is an Interferon a2b (IFNa2b) based potential treatment that is proposed to be administered using a Metered Dose Inhaler (MDI) or a nebulizer.
Field of Use
The field of use is a potential COVID-19 treatment proposed to be administered using a Metered Dose Inhaler (MDI) or a nebulizer.
IPSCIO Record ID: 262807
License Grant
The Company entered into an agreement with a manufacturer of the nebulizer for the use to administer Molgradex.
License Property
Molgradex (an inhalation formulation of recombinant human GM-CSF for the treatment of aPAP) for the treatment of severe pulmonary conditions. Molgradex is administered to the lungs using the investigational eFlow® Nebulizer System.
Molgradex, is a sterile nebulizer solution in a vial containing 300 µg of molgramostim, designed to be administered once daily by inhalation via a high efficiency Investigational eFlow Nebulizer System. The PARI eFlow Nebulizer system for use with investigational drug products is a reusable electronic inhalation system that has been optimized for administration of Molgradex.
“aPAP†– autoimmune pulmonary alveolar proteinosis
“CF†– nontuberculous mycobacterial (“NTMâ€) lung infection n individuals living with cystic fibrosis
AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin-resistant Staphylococcus aureus (“MRSAâ€) lung infection in individuals living with CF.
Field of Use
This agreement pertains to the drug industry.
IPSCIO Record ID: 352007
License Grant
Licensor granted to Party A, during the term of the Agreement, an exclusive, worldwide, fee-bearing license derived from the licensed intellectual property throughout the world. Licensee and Party A merged resulting in Licensee now owes the royalty payments to Licensor.
License Property
Licensed Intellectual Property includes but not limited to the Niclosamide Product.
ANA001, our lead drug candidate, is a proprietary oral niclosamide formulation and was developed as a treatment for patients with moderate COVID-19. Niclosamide is a potential oral antiviral and anti-inflammatory agent with a long history of use and well-understood safety in humans.
Field of Use
Field of use is for the treatment of COVID-19, a viral disease.
IPSCIO Record ID: 265768
License Grant
The Japanese Licensee received an exclusive right to import, market, sell, distribute and promote Molgradex in Japan for the treatment of aPAP.
License Property
Molgradex (an inhalation formulation of recombinant human GM-CSF for the treatment of aPAP) for the treatment of severe pulmonary conditions. Molgradex is administered to the lungs using the investigational eFlow® Nebulizer System.
Molgradex, is a sterile nebulizer solution in a vial containing 300 µg of molgramostim, designed to be administered once daily by inhalation via a high efficiency Investigational eFlow Nebulizer System. The PARI eFlow Nebulizer system for use with investigational drug products is a reusable electronic inhalation system that has been optimized for administration of Molgradex.
“aPAP†– autoimmune pulmonary alveolar proteinosis.
“NTM†– nontuberculous mycobacteriallung infection n individuals living with cystic fibrosis (“CFâ€)
AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin-resistant Staphylococcus aureus (“MRSAâ€) lung infection in individuals living with CF.
Field of Use
Molgradex is the first treatment being developed for inhalation of GM-CSF (Granulocyte Macrophage-Colony Stimulating Factor) for the treatment of patients suffering from a rare respiratory disease called autoimmune pulmonary alveolar proteinosis (aPAP).
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
